期刊文献+

人可溶性B7-2分子的定量检测及应用

The quantitative determination of human soluble B7-2 molecule and its application
下载PDF
导出
摘要 选取识别不同抗原位点的鼠抗人B7-2单抗1F9和6C8分别作为包被和检测抗体,用生物素(Biotin)标记检测抗体,建立双单抗夹心的sB7-2检测方法。在对其特异性、稳定性和准确性进行分析的基础上,对20例系统性红斑狼疮(S1,E)患者及30名健康献血者血清中sB7-2的含量进行了测定。建立的sB7-2检测方法的灵敏度为0.15ng/ml,具有良好线性关系的检测范围0.31~20.00ng/ml。单抗1F9包被的测定板,4℃放置30d内,工作曲线中各测定点的变异系数〈5.9%。sLE患者血清中sB7-2的含量为(2.207±0.517)ng/ml,与健康献血者的(1.275±0.263)ng/ml比较具有统计学的显著差异(p〈0.01)。本研究中建立的人sB7-2检测方法,能够对血清中sB7-2进行定量分析,可为该分子的基础研究及临床相关疾病的辅助诊断与判断预后提供参数。 A method of quantitative determination of human soluble B7-2 molecule was established by using the mouse antihuman B7-2 monoclonal antibody 1F9 and 6C8 recognizing different antigenic epitopes on this molecule as the coating and detecting antibodies and the biotin-labeled monoclonal antibody in the double monoclonal antibody sandwich ELISA assay. The fusion protein B7-2/Fc was used as the standard antigen. On the basis of analysis in its specificity, stability and accuracy, the contents of soluble B-2 molecule in sera of 20 cases with systemic lupus erythematosus(SLE) and 20 healthy volunteers were determined by using this method. It was found that this method was proved to be quite sensitive, specific and stable, with a detecting limit of 0.15 ng/ml and a better linear range of standard curve of 0.31-20.00 ng/ml. As determined by this method, no cross reaction could be detected with the monoclonal antibody against B7-1Fc. The concentrations of B7-2 in sera from SLE and healthy volunteers were (2. 207 ± 0. 517) ng/ml and (1. 275 ± 0. 263) ng/ml respectively,with significant statistical difference between these two groups(P〈0.01). This method may provide further data of serological diagnosis and prognosis for the related diseases.
出处 《现代免疫学》 CAS CSCD 北大核心 2007年第5期359-363,共5页 Current Immunology
基金 江苏省高校高新技术产业发展基金资助项目(JHB05-45) 江苏省自然科学基金资助项目(BK2004203)
关键词 可溶性B7-2 ELISA 生物素 系统性红斑狼疮 soluble B7-2 molecule ELISA biotin systemic lupus erythematosus
  • 相关文献

参考文献14

  • 1Sharpe AH,Freeman GJ.The B7-CD28 superfamily[J].Nat Rev Immunol,2002,2(2):116-126.
  • 2Orabona C,Grohmann U,Belladonna ML,et al.CD28 induces immunostimulatory signals in dentritic cells via CD80 and CD86[J].Nat Immunol,2004,5 (11):1134-1142.
  • 3Kurlber G,Chopra K,Kulkarni SK,et al.Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway[J].Clin Exp Immunol,2007,147(1):155-163.
  • 4Kurlberg G,Haglind E,Scttn K,et al.Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs[J].Scand J Immunol,2000,51(3):224-230.
  • 5Mcadam AJ,Leach DR,Tada Y,et al.Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differention of CD4+ T cell[J].J Immunol,2000,165(6):5035-5040.
  • 6Anthony J,Coyle JC,Gutierrez R.The expanding B7 superfamily:increasing complexity in costimulatory signals regulating T cell function[J].Nat Immunol,2001,2(3):203-209.
  • 7Wong CK,Lit LCW,Tam LS,et al.Aberrant production of soluble costimulatory molecules CTLA-4,CD28,CD80 and CD86 in patients with systemic lupus erythematosus[J].Rheumatology,2005,44(10):989-994.
  • 8Fife BT,Griffin MD,Abbas AK,et al.Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist[J].J Clin Invest,2006,116(8):2280-2283.
  • 9Tsutsumi Y,Jie X,Ihara K,et al.Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes[J].Diabet Med,2006,23(10):1145-1150.
  • 10Ip WK,Wong CK,Leung TF,et al.Plasma concentrations of soluble CTLA-4,CD28,CD80 and CD86 costimulatory molecules reflect disease severity of acute asthma in children[J].Pediatr Pulmono,2006,41(7):674-682.

二级参考文献24

  • 1Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation[J]. Annu Rev Immunol, 1996,14:233-258.
  • 2Freeman GJ,Gribben JG,Boussiotis VA, et al. Cloning of B7.2:CTLA-4 counter-receptor that costimulate human T cell proliferation[J]. Science, 1993,262:909-911.
  • 3Lewis L, Shawn O, Chamorro S, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL[J]. J lmmunol,1995,154:97-105.
  • 4Beatriz M, Mary C. The B7 family of ligands and its receptors:new pathways for costimulation and inhibition of immune responses[J]. Annu Rev Immunol, 2002,20:29-53.
  • 5Boussiotis VA, Freeman GJ, Gribben JG, et al. Activated human B lymphocytes express three CTLA-4 counter receptors that costimulate T-cell activation[J]. Proc Natl Acad Sci USA, 1993,90:11059-11063.
  • 6Azuma M, Ito D, Yagita H, et al. B7-0 antigen is a second ligand for CTLA-4 and CD28[J]. Nature,1993,366:76-79.
  • 7Thomas JL, Phuong N, Robert P, et al. In vivo CD86 blockade inhibits CD4^+ T cell activation whereas CD80 blockade potentiates CD8^+ T cell activation and CTL effector function [J]. J Immunol, 2002,168:3786-3792.
  • 8David M, Claire N, Yong Z. What′s the difference between CD80 and CD86[J]. Trends Immunol, 2003,24(6):313-318.
  • 9Martin-Fontecha A, Cavallo F, Bellone M, et al. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors[J].Eur J Immunol, 1996,26(8): 1851-1859.
  • 10Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenges in vitro inhibits Th1 cytokines but spares Th2[J]. J Exp Med, 1995,181(5):1869-1874.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部